MedTrace Logo

Aromatherapy for Chemotherapy-induced Nausea and Vomiting (CINV)

NCT05319860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-04-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the use of aromatherapy to reduce nausea, vomiting, and the use of anti-emetic in cancer survivors undergoing moderate to highly emetogenic chemotherapy regimens.

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG

Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)

Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.

DRUG

Aromatherapy Care

An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Debbie Anglade, PhD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2024-04-15
Completion
2024-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05319860 on ClinicalTrials.gov